Document is current
Any future updates will be listed below
-
Authors
Flanigan, Meghan E. http://orcid.org/0000-0002-3185-7459
Aleyasin, Hossein
Li, Long
Burnett, C. Joseph http://orcid.org/0000-0002-3107-0146
Chan, Kenny L.
LeClair, Katherine B.
Lucas, Elizabeth K. http://orcid.org/0000-0002-0632-4538
Matikainen-Ankney, Bridget
Durand-de Cuttoli, Romain http://orcid.org/0000-0003-0240-7608
Takahashi, Aki
Menard, Caroline http://orcid.org/0000-0001-8202-7378
Pfau, Madeline L.
Golden, Sam A. http://orcid.org/0000-0002-2104-2272
Bouchard, Sylvain
Calipari, Erin S. http://orcid.org/0000-0003-4723-0623
Nestler, Eric J. http://orcid.org/0000-0002-7905-2000
DiLeone, Ralph J.
Yamanaka, Akihiro
Huntley, George W. http://orcid.org/0000-0003-3645-6192
Clem, Roger L. http://orcid.org/0000-0002-8965-9455
Russo, Scott J. http://orcid.org/0000-0002-6470-1805
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH114882, R01MH090264, P50MH096890, F31MH111108, T32MH096678, T32MH087004, R01MH51399)
- License Information
-
More Information
Article History
Received: 23 August 2018
Accepted: 2 March 2020
First Online: 13 April 2020
Competing interests
: S.J.R. and M.E.F. have a patent pending (US Patent Application 62/11,233) for the use of OxR2 antagonists to treat aggression.
